



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 307/93, 493/04, A61K 31/34, 31/495, 31/445, 31/535 // (C07D 493/04, 313:00, 307:00)	A1	(11) International Publication Number: WO 97/38991 (43) International Publication Date: 23 October 1997 (23.10.97)
(21) International Application Number: PCT/EP97/01829 (22) International Filing Date: 9 April 1997 (09.04.97) (30) Priority Data: 96200990.8 12 April 1996 (12.04.96) EP (34) Countries for which the regional or international application was filed: DE et al. (71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. (BE/BE); Turnhoutseweg 30, B- 2340 Beerse (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): GIL-LOPETEGUI, Pi- lar [ES/ES]; Santa Ursula, 10, E-45002 Toledo (ES). FERNÁNDEZ-GADEA, Francisco Javier [ES/ES]; Sagra No. 20, Cerro De Las Perdices, E-45593 Toledo (ES). MEERT, Theo, Franz [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).		(81) Designated States: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
(54) Title: SUBSTITUTED TETRACYCLIC TETRAHYDROFURAN DERIVATIVES (57) Abstract This invention concerns the compounds of formula (I), the <i>N</i>-oxide forms, the pharmaceutically acceptable addition salts and the stereoisomeric forms thereof, wherein <i>n</i> is zero to 6; <i>p</i> and <i>q</i> are zero to 4; <i>r</i> is zero to 5; <i>R</i>¹ and <i>R</i>² each independently are hydrogen; optionally substituted C₁-alkyl; C₁-alkylcarbonyl; halomethylcarbonyl; or <i>R</i>¹ and <i>R</i>² taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; each <i>R</i>³ and <i>R</i>⁴ independently are halo, cyano, hydroxy, halomethyl, halomethoxy, carboxyl, nitro, amino, mono- or di(C₁-alkyl)amino, C₁-alkylcarbonylamino, aminosulfonyl, mono- or di(C₁-alkyl)aminosulfonyl, C₁-alkyl, C₁-alkyloxy, C₁-alkylcarbonyl, C₁-alkyloxycarbonyl; each <i>R</i>⁵ independently is C₁-alkyl, cyano or halomethyl; <i>X</i> is CR⁶R⁷, NR⁸, O, S, S(=O) or S(=O)₂; aryl is optionally substituted phenyl; provided that the compound is other than (±)-3,3a,8,12b-tetrahydro-<i>N</i>-methyl-2<i>H</i>-dibenzo[3,4:6,7]-cyclohepta[1,2-<i>b</i>]-furan-2-methanamine oxalic acid. The compounds of formula (I) may be used as therapeutic agents in the treatment or the prevention of CNS disorders, cardiovascular disorders or gastrointestinal disorders.		